Effects of Evolocumab on Cardiovascular Events

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Evolocumab is a highly effective lipid-lowering agent, reducing low-density lipoprotein cholesterol (LDL-C) by 50-60%.
• The FOURIER trial is a major randomized study including 27,564 patients with existing cardiovascular disease, treated with statins, and LDL-C levels above 70 mg/dl.

Purpose of the Study:

• To assess the impact of evolocumab on the occurrence of cardiovascular events in high-risk patients.
• To evaluate the efficacy and safety of evolocumab as an adjunct to statin therapy.

Main Methods:

• A large-scale, randomized, placebo-controlled trial (FOURIER) was conducted.
• Participants had established cardiovascular disease, were on statin therapy, and had elevated LDL-C levels.
• The study involved a mean follow-up period of 2.2 years.

Main Results:

• Evolocumab demonstrated a significant 15% reduction in the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or revascularization) compared to placebo.
• No significant impact on overall mortality was observed.
• The most frequent adverse event was mild injection site reactions, occurring slightly more in the evolocumab group (2.1%) than placebo (1.6%).

Conclusions:

• Evolocumab is a beneficial add-on therapy for high-risk cardiovascular patients who do not reach target LDL-C levels with statins alone.
• Further long-term research is warranted to fully elucidate the long-term efficacy and safety profile of evolocumab.